Dateline City:
KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.
KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Eisai Inc. today announced new interim data investigating Mercks
anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination
with Eisais microtubule dynamics inhibitor, HALAVEN
(eribulin), in patients with metastatic triple-negative breast cancer
(TNBC).
Language:
English
Contact:
Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more